PubMed Health⌕ Search

PubMed · 12493335

Living with a variable disease.

Abstract

Asthma is a variable disease which, when not fully controlled, may leave the patient with a sense of bewilderment, fear, anger and a loss of many 'normal' activities of daily living. The reasons for these fears range from the concern of having an asthma attack to concerns about taking medications, perhaps especially steroids. Complex treatment regimens and a lack of understanding by the patient of their asthma may lead to denial and a reduction in adherence to medication resulting in poor treatment outcomes. Patients' lack of understanding may originate from poor communication between patient and physician. Improved communication and ensuring that all of the patient's questions are answered, as well as simpler treatment regimens may improve asthma control. Detailed, written personal asthma action plans should act as a foundation for building good relationships between doctor and patient and enhance adherence. Simplifying treatment regimens, such as having an inhaled corticosteroid and a long-acting, beta(2)-agonist in a single inhaler, used in conjunction with these personal asthma action plans, should provide a therapy that enables patients to be in control of their asthma without having to live in fear of their illness.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M R Partridge. 2002. Living with a variable disease.. https://doi.org/10.1006/pupt.2002.0399

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Concurrent carbogen and radiation therapy in children with high-risk brainstem gliomas.

In an attempt to improve local control, we assessed the feasibility of the addition of 4 min of carbogen inhalation (as a radiosensitizer) to daily fractionated radiotherapy in pediatric patients with high grade and/or diffuse brainstem gliomas. Ten patients inhaled carbogen for >90% of the radiation treatments. Median survival time from start of therapy was 0.80 years. Carbogen inhalation did not appear to improve the dismal prognosis.

Administration, Inhalation↗

2. Advances in pharmacotherapy for COPD.

Chronic obstructive pulmonary disease (COPD) is the most common chronic lung disease in the world. In 1999, COPD ranked sixth among the most common causes of death and twelfth as a worldwide burden of disease. It has been estimated that by the year 2020 COPD will be the third leading cause of death and fifth as a worldwide burden of disease. Thus, COPD is a major medical problem and there is evidence that it is increasing throughout the world. Despite recognition of COPD as an important international health problem, COPD has been neglected among common diseases, with little investment in research on its underlying cellular and molecular mechanisms. Recently, global and Japanese guidelines for COPD have been published. These guidelines seem to be useful to improve the underdiagnosis and undertreatment of COPD. In this review, I describe briefly the current recommendation for pharmacological therapy of stable COPD according to the global and Japanese guidelines for COPD.

Administration, Inhalation↗